Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.Arthritis research & therapy · 2019
   Pooled it
2. Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study.Acta dermato-venereologica · 2021
   Trial
3. Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.Journal of the European Academy of Dermatology and Venereology : JEADV · 2019
   Trial
4. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.Archives of dermatological research · 2024
   Observational
5. Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022
   Article
6. Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis.Dermatology and therapy · 2022
   Review
7. Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.Acta dermato-venereologica · 2022
   Article
8. Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24 Months of Follow-Up: Results from US Dermatology Electronic Medical Records.Dermatology and therapy · 2021
   Article
9. IgA vasculitis during secukinumab therapy.Clinical rheumatology · 2021
   Review
10. Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations.Annals of dermatology · 2021
    Article
11. Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities.Dermatology and therapy · 2021
    Review
12. Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry.Dermatology (Basel, Switzerland) · 2021
    Observational
13. Pharmacological Management of Pediatric Pustular Psoriasis.Paediatric drugs · 2020
    Article
14. Secukinumab in the treatment of psoriasis: patient selection and perspectives.Psoriasis (Auckland, N.Z.) · 2018
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.